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HPV-PISH autoradiographs on DNA.
(a) 3 +, (c) 2 +, (b) and (d) 1 +, oesophageal carcinomas; (e) negative
oesophageal carcinoma; (f) hela cell line containing HPV-18 DNA sequences9
and used as positive control.
the carcinomas and of adjacent non-neoplastic oesophageal
epithelium were examined histologically. Binucleation and/or
perinuclear clearing similar to koilocytosis was noted in epithelium
adjacent to carcinoma tissue in about 25% of the cases. However,
distinctive changes identifiable as definite HPV effect were not seen.
The complex of appearances attributable to HPV in the cervix-
koilocytosis with nuclear atypia, multinucleation, papillomatosis,
parakeratosis, and basal cell hyperplasia-was not present in any
case. On examination of the tissue for genus-specific HPV capsid
antigen by the avidin-biotin immunoperoxidase method (Vector
Laboratories, Burlingame, California) no case was positive, either in
the tumour or in adjacent squamous epithelium.
DNA hybridisation studies were done in 10 cases of oesophageal
carcinoma using a method developed for paraffin-embedded
material, the accuracy being verified by one of us (J. K.) using tissue
and smears of cervical HPV infections. The method involves a
combination of extraction of nuclei from tissue7 and filter in-situ
hybridisation (FISH).8. Hybridisation was done under stringent
conditions, using a mixed probe of HPV types 11, 13, 16, and 18
obtained from Dr H. zur Hausen and Dr L. Gissmann (Deutsche
KrebsforschungsZentrum, Heidelberg, West Germany). In 5 cases
oesophageal carcinoma tissue was positive. 1 case was graded 3 +
positive (figure, a), 1 as 2 + positive (c), and 2 cases showed only
minor positivity (b and d).
The DNA hybridisation method used here is being further
evaluated for sensitivity and specificity. However, from these
preliminary observations it seems that HPV DNA is present in
some oesophageal carcinomas in a low-risk area and that HPV is
worthy of further investigation as a possible aetiological factor in
oesophageal carcinoma. Hybridisation of DNA extracted from
paraffin-embedded material could be applied to archival tissue from
various body sites, offering a simple screening test for the detection
of viral DNA and, perhaps, other DNA in tissues.
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DR2-NEGA TIVE NARCOLEPSY
SiR,&mdash;A recent addition to the long list of HLA-associated
diseases is narcolepsy (with DR2).1-3 The association seems strong,
DR2 being found in 100% of cases with narcolepsy in some series.
However, in a study of 118 such patients (21 from Munich, 97 from
Prague) we found 4 who lacked DR2 on duplicate HLA DR/DQ
serotyping with confirmatory tests with gene probes for DR and
DQ P chains.
Rigorous clinical evaluation included sleep laboratory studies in
most patients and only patients with an unequivocal diagnosis of
narcolepsy were included.
The 4 DR2 negative narcolepsy patients possess either DR4 or
DR5 or both, and all are positive for DQw3 (table). In 4 other
published DR2-negative cases" DR types are provided for 3
(DR1/DR4, DR1/DR3, DR4/DR7).
HLA PHENOTYPES OP DR2-NEGATIVE NARCOLEPSY PATIENTS
2 of our 4 patients had the full picture of narcolepsy, including
cataplexy, and cannot be distinguished clinically from DR2-
positive cases. However, the other 2 did not have cataplexy. 6 out of
6 additional patients from Prague with narcolepsy after organic
brain damage (encephalitis or brain trauma) were positive for DR2
and all had cataplexy. Perhaps a genetic predisposition to narcolepsy
existed before the organic brain damage, which may or may not
have contributed to the onset of narcolepsy.
EcoRI digest of genomic DNA from narcolepsy patients, hybridised
with a DQ-[3 probe (P. Peterson).
10 patients DR2 positive, 1 patient (patient 1) DR2 negative (arrow).
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We have not identified any DR-0 polymorphism which
correlates with a subtype of DR2 in narcolepsy. However, with an
EcoRI digest of genomic DNA and a DQ-0 probe we have
identified a 2-7 kb band, correlating with DR2 and DRwl3 (a
subtype of DRw6),7 which is almost certainly identical to DQR2 6
(figure). We have found this DQR2 band in all 27 DR2-positive
patients tested at the DNA level so far, which confirms the data of
Marcadet et al .8 In the DR2-negative patients, however, we do not
find this band (figure), except in the patient with DR4, DRw6.
where it would be expected (on the DRw6 haplotype). In
DR2-positive healthy controls we found the DQR2-6 band in 19 of
21 cases-ie, much more frequently than in Marcadet’s controls.
However, our DR2-positive healthy panel contained a high
proportion of DR2 individuals who carried HLA-B7 (11 of 21), a
combination strongly associated with DQR2’6.
We conclude that narcolepsy cannot be excluded just because the
patient is negative for DR2 and that the DQR2 subtype of DQwl,
which has been found to be highly associated with narcolepsy, is
negative in the DR2-negative patients. It remains to be seen
whether DR2-negative narcolepsy patients have any HLA antigens
in common.
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SPIROCHAETES, LYME DISEASE, AND
MULTIPLE SCLEROSIS
SIR,-Dr Muhlemann and colleagues (May 10, p 1097) and Dr
Fumarola (Sept 6, p 575) state that we have proposed an association
between multiple sclerosis (MS) and Borrelia burgdorferi, the
causative organism of Lyme disease. This is not so. Lyme disease,
being exclusively a tick-bome infection with characteristic
epidemiological features (localised epidemics, restricted to persons
exposed to specific ticks and occurring in the summer months) is
wholly inconsistent with the epidemiology of MS. Moreover,
Muhlemann et al have found no serological evidence to support
B burgdorferi, or any other closely related Borrelia sp, as a possible
cause of MS.
What we did note (April 12, p 819) is that spirochaetal infections,
such as Lyme disease, have many of the "immunological and
pathological characteristics of MS", suggesting the possible
spirochaetal aetiology of that disease. Indeed we think that MS may
be caused by a treponemal spirochaete that invades the central
nervous system through defects in the wall of the sphenoidal sinus
(July 12, p 75), and we have evidence from immunofluorescence
and western blot studies that an organism of this type is present in
the central nervous system in active MS (unpublished).
We should point out, however, that there is now clear evidence
that B burgdorferi may occasionally cause demyelination as a sequel
to Lyme diseases It seems inevitable that some patients, especially
in areas where Lyme disease is endemic, who have been labelled as
"possible MS", will - ultimately be shown to have Lyme
demyelinating encephalopathy. A search for these patients should
be undertaken in endemic areas.
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AMINOACID LOSSES ON HAEMOFILTRATION
SIR,-Intravenous aminoacid solutions are often given to
patients with acute renal failure who cannot be fed enterally.
Aminoacid losses on conventional haemodialysis are smalP but
little is known about losses during haemofiltration because the
molecular weight cut-off for the filter (30 000 or more) is much
greater than the molecular weights of individual aminoacids.
Continuous veno-venous haemofiltration (CVVHF) was used in
the treatment of a 29-year-old woman in acute renal failure due to
Goodpasture’s syndrome and who was also unconscious due to
vasogenic cerebral oedema. 24 litres of haemofiltrate were collected
daily for 7 days via a Gambro FHSS haemofilter, the rate then being
reduced to 12 litres per day for a further 7 days. During this period
she received no oral feeding, remained anuric, and passed no faeces.
She was parenterally fed, whilst on CVVHF, with 500 ml of 50%
dextrose with insulin and added vitamins, 1 litre of ’Vamin 9’ by
continuous infusion over 24 h, and 250 ml of 20% ’Intralipid’ each
day. Haemofiltrates were collected for each 24 hour period with a
corresponding timed serum sample and assayed for aminoacid
content (’Chromaspek’; Rank Hilger, Margate). Samples were
analysed daily for each week at the two different filtration rates, and
the results are expressed as mean (and standard error) for 7 days. A
SERUM AMINOACID PROFILES AND CLEARANCES IN PATIENT ON
HAEMOFILTRATION AT RATES OF 24 (A) AND 12 (B) LITRES DAILY:
MEAN (AND STANDARD ERROR)
Creatinine clearances were 25-5 ml/min (SE 1 -56) for 24 litres daily and 8 08 ml/min (SE
0-48) for 12 litres daily.
*p < 0-05, tp < 0 01, zip < 0 001; otherwise differences were not sigmficant.
